Clinical Trials Logo

Clinical Trial Summary

The primary objective is to explore the efficacy and safety of azacytidine and HAG regimen versus azacytidine for elderly patients with Newly Diagnosed MDS/AML/CMML in China. This is a post-marketing, interventional, multi-center, double-arm, prospective, open-label, randomized controlled study in elderly patients with MDS/AML/CMML in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be given azacytidine + HAG regimen or azacytidine under the conditions of informed consent and frequent monitoring according to the clinical guideline.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myelomonocytic, Juvenile
  • Myelodysplastic Syndromes

NCT number NCT03873311
Study type Interventional
Source Shenzhen Second People's Hospital
Contact
Status Recruiting
Phase Phase 4
Start date September 1, 2019
Completion date June 1, 2023